NR4A1 and deep vein thrombosis: In a mouse experiment, the number of inflammatory Ly6Chi monocytes controls DVT formation, growth, and regression, and Nur77 agonist may be an ideal candidate for therapeutic intervention with inflammatory monocyte activity in patients with DVT to prevent thrombosis growth and accelerate regression (250).